Nasdaq:TECH
BIO-TECHNE Corp
A leading global provider of research tools and reagents for life sciences laboratories with a strong focus on antibody and assay technology.
Key Metrics
Investment Thesis
Bull Case
Despite recent earnings contraction, Bio-Techne maintains a fortress-like cash position and generates robust operating cash flow that exceeds net income, providing a safety margin for strategic pivots. The company's diverse product portfolio across multiple therapeutic areas reduces dependency on any single market segment, offering resilience against industry-specific downturns. Continued share repurchases signal management confidence in intrinsic value and commitment to returning capital to shareholders.
Bear Case
The sharp decline in net income over the past two years combined with rising accumulated other comprehensive losses suggests deteriorating operational efficiency or unrecognized liabilities. Heavy reliance on non-cash adjustments inflates reported profits relative to actual cash generation potential, masking underlying profitability challenges. Elevated accounts receivable and significant debt obligations from revolver draws create liquidity pressure that could worsen if revenue growth stalls further.
About BIO-TECHNE Corp
Bio-Techne Corp. specializes in life sciences research tools and reagents, serving academic, industrial, and government laboratories globally. The company operates through two main segments: Reagent Discovery, which provides assay kits and proteins for target discovery, and Life Science Products, offering antibodies and diagnostics for protein analysis. With a diverse portfolio of over 200 products, Bio-Techne enables researchers to explore biological mechanisms and develop new therapies.
Analysis
Management Discussion
Bio-Techne generated strong operating cash flow of $287.6M in the latest period, significantly exceeding its net profit of $73.4M due to non-cash adjustments totaling $205.8M. However, revenue growth has been modest at 5% year-over-year while profitability contracted sharply, indicating potential headwinds in pricing power or increased cost of goods sold. The company maintained a stable cash balance despite substantial financing outflows driven by debt refinancing and buyback activities.
Industry Overview
The life sciences research tools industry is driven by increasing demand for biomarkers and diagnostic reagents as therapeutic development pipelines expand globally. Competition remains intense among suppliers of antibodies and assay kits, with consolidation trends favoring firms offering broad portfolios and strong distribution networks. Regulatory scrutiny on clinical trial data integrity and supply chain transparency continues to shape operating standards in this sector.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $1.14B | $1.16B | $1.22B |
| Cost of Revenue | $366.9M | $389.3M | $429.4M |
| Gross Profit | $769.8M | $769.7M | $790.3M |
| Operating Expenses | $470.9M | $563.0M | $688.0M |
| Operating Income | $298.9M | $206.7M | $102.3M |
| G&A | $378.4M | $466.4M | $588.5M |
| Stock-Based Comp | $39.2M | $38.0M | $40.8M |
| D&A | $107.2M | $111.7M | $109.9M |
| Depreciation | — | — | $34.6M |
| Amortization | $77.5M | $79.9M | $76.0M |
| Other OpEx | $92.5M | $96.7M | $99.5M |
| Non-Operating Income | $39.7M | $-21.0M | $-3.8M |
| Interest Expense | $11.2M | — | — |
| Pre-Tax Income | $338.7M | $185.7M | $98.5M |
| Income Tax | $53.2M | $17.6M | $25.1M |
| Continuing Ops | $285.4M | $168.1M | $73.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $285.4M | $168.1M | $73.4M |
| Minority Interest | $179.0K | $0 | $0 |
| Net to Common | $285.3M | $168.1M | $73.4M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $621.5M | $617.4M | $608.3M |
| Cash & Equivalents | $180.6M | $151.8M | $162.2M |
| Marketable Securities | $23.7M | $1.1M | — |
| Accounts Receivable | $218.5M | $241.4M | $206.9M |
| Inventory | $171.6M | $179.7M | $189.4M |
| Other Current Assets | $27.1M | $43.4M | $49.8M |
| Long-Term Assets | $2.02B | $2.09B | $1.95B |
| PP&E (Net) | $226.2M | $251.2M | $245.7M |
| Intangibles | $534.6M | $507.1M | $365.6M |
| Goodwill | $872.7M | $972.7M | $980.9M |
| Operating Leases | $98.3M | $91.3M | $73.4M |
| Other LT Assets | $29.4M | $21.9M | $47.9M |
| Total Assets | $2.64B | $2.70B | $2.56B |
| Current Liabilities | $128.5M | $159.4M | $175.8M |
| Accounts Payable | $25.7M | $38.0M | $25.3M |
| Current Leases | $11.2M | $12.9M | $14.1M |
| Deferred Revenue | $23.1M | $27.9M | $32.6M |
| Taxes Payable | $12.0M | $3.7M | $10.8M |
| Other Current Liab | $41.7M | $52.0M | $67.4M |
| Long-Term Liabilities | $543.7M | $475.6M | $463.2M |
| LT Operating Leases | $93.8M | $87.6M | $84.0M |
| Other LT Liab | $449.9M | $388.0M | $33.3M |
| Total Liabilities | $672.2M | $635.0M | $639.1M |
| Shareholders' Equity | $1.97B | $2.07B | $1.92B |
| Retained Earnings | $1.31B | $1.33B | $1.07B |
| AOCI | $-66.1M | $-78.3M | $-59.9M |
| Total L&E | $2.64B | $2.70B | $2.56B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $285.4M | $168.1M | $73.4M |
| Non-Cash Adjustments | $-51.7M | $65.2M | $205.8M |
| Working Capital Changes | $20.7M | $65.7M | $8.3M |
| Cash from Operations | $254.4M | $299.0M | $287.6M |
| Capital Expenditures | $38.2M | $62.9M | $31.0M |
| Cash from Investing | $-265.6M | $-203.0M | $-35.2M |
| Share Buybacks | $19.6M | $80.0M | $275.7M |
| Dividends Paid | $50.3M | $50.4M | $50.4M |
| Cash from Financing | $22.6M | $-122.4M | $-253.9M |
| FX Effect | $-3.4M | $-2.3M | $11.9M |
| Net Change in Cash | $8.0M | $-28.8M | $10.4M |
| Beginning Cash | $172.6M | $180.6M | $151.8M |
| Ending Cash | $180.6M | $151.8M | $162.2M |
Frequently Asked Questions
How does BIO-TECHNE Corp make money?
1) Reagent Discovery: Supplies assay kits, proteins, and small molecules for target discovery and validation across various disease areas. 2) Life Science Products: Offers antibodies, antigens, and diagnostic kits used for protein characterization and biomarker development in research settings.
What are the main risks for TECH?
1) Declining net income trend from $285.4M in 2023 to $73.4M in 2025 raises concerns about margin compression or one-off charges. 2) High accounts receivable relative to cash reserves ($206.9M vs $162.2M) suggests potential collection delays or aggressive revenue recognition. 3) Significant share repurchases and dividends consuming cash flow could limit future R&D flexibility if earnings do not recover.
What is TECH's competitive advantage?
1) Extensive proprietary product portfolio with over 200 unique SKUs that reduce reliance on single suppliers. 2) Strong relationships with key academic and industrial partners fostering long-term collaboration and repeatable revenue streams. 3) Robust cash position enabling strategic investments in R&D and market expansion despite high capital expenditures.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.